Literature DB >> 550136

Methadone disposition during the perinatal period in humans.

M J Kreek.   

Abstract

To determine clinical and analytical feasibility of studies of narcotic disposition in the perinatal period, an initial prospective study of methadone disposition in one female, in chronic methadone treatment for heroin addiction, throughout pregnancy and in her neonate have been carried out. Two additional methadone-maintained patients were studied to determine the levels of methadone in simultaneously obtained specimens of plasma and breast milk. A progressive lowering of plasma levels of methadone during late pregnancy was observed. Measurable amounts of methadone were found in amniotic fluid, but without evidence of significant accumulation in this fluid. The apparent excretory half-life of methadone in the neonate was 32.5 hr. Amounts of methadone in breast milk were very small; the ratio of milk to plasma concentrations ranged from 0.05 to 1.2 over multiple time points following a daily oral dose of methadone. The total amounts of methadone which could be delivered to a neonate during the first month of life in breast milk from a mother maintained on moderate doses of methadone (e.g., 50 mg) are very small (less than 60 micrograms/d).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 550136

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  12 in total

1.  Concentrations of methadone in breast milk and plasma in the immediate perinatal period.

Authors:  Lauren M Jansson; Robin E Choo; Cheryl Harrow; Martha Velez; Jennifer R Schroeder; Ross Lowe; Marilyn A Huestis
Journal:  J Hum Lact       Date:  2007-05       Impact factor: 2.219

Review 2.  Detoxification considerations in the medical management of substance abuse in pregnancy.

Authors:  M H Allen
Journal:  Bull N Y Acad Med       Date:  1991 May-Jun

3.  Estimated infant exposure to enantiomer-specific methadone levels in breastmilk.

Authors:  Debra L Bogen; James M Perel; Joseph C Helsel; Barbara H Hanusa; Matthew Thompson; Katherine L Wisner
Journal:  Breastfeed Med       Date:  2011-02-24       Impact factor: 1.817

4.  Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome.

Authors:  Teresa R Gray; Robin E Choo; Marta Concheiro; Erica Williams; Andrea Elko; Lauren M Jansson; Hendreé E Jones; Marilyn A Huestis
Journal:  Addiction       Date:  2010-09-20       Impact factor: 6.526

5.  A woman's experience of tapering from buprenorphine during pregnancy.

Authors:  Gabrielle Katrine Welle-Strand; Odd Kvamme; Andreas Andreassen; Edle Ravndal
Journal:  BMJ Case Rep       Date:  2014-12-24

6.  A validated liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometric method for the quantification of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and 2-Ethyl-5-methyl-3,3-diphenylpyroline (EMDP) in human breast milk.

Authors:  Robin E Choo; Lauren M Jansson; Karl Scheidweiler; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2007-06       Impact factor: 3.367

7.  Steady-state methadone effect on generalized arousal in male and female mice.

Authors:  N Devidze; Y Zhou; A Ho; Q Zhang; D W Pfaff; M J Kreek
Journal:  Behav Neurosci       Date:  2008-12       Impact factor: 1.912

8.  Methadone maintenance and long-term lactation.

Authors:  Lauren M Jansson; Robin Choo; Martha L Velez; Ross Lowe; Marilyn A Huestis
Journal:  Breastfeed Med       Date:  2008-03       Impact factor: 1.817

Review 9.  Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases.

Authors:  Yan Zhou; Dmitri Proudnikov; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Brain Res       Date:  2009-11-12       Impact factor: 3.252

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.